Androgen receptor (AR) is closely associated with a group of hormone‐related diseases
including the cancers of prostate, breast, ovary, pancreas, etc and anabolic deficiencies …

Androgen receptor (AR) signaling is a key driver of prostate cancer (PC). While androgen-
deprivation therapy is transiently effective in advanced disease, tumors often progress to a …

Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease,
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …

Background The androgen receptor (AR) is a pivotal drug target for the treatment of prostate
cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR …

Androgen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches
for AR inactivation include chemical castration, inhibition of androgen synthesis and AR …

There has been a resurgence of interest in the development of androgen receptor (AR)
inhibitors with alternative modes of action to overcome the development of resistance to …

Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant
prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain of the AR …

Prostate cancer (PCa) progression relies on androgen receptor (AR) action. Preventing AR's
ligand-activation is the frontline treatment for metastatic PCa. Androgen deprivation therapy …

Abstract Nuclear Receptors (NRs) are multi-domain proteins, whose natural regulation
occurs via ligands for a classical, orthosteric, binding pocket and via intra-and inter-domain …

Spinal bulbar muscular atrophy (SBMA) is a motor neuron disease caused by toxic gain of
function of the androgen receptor (AR). Previously, we found that co-regulator binding …